Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by CHICAGO TRUST Co NA

CHICAGO TRUST Co NA reduced its stake in Exact Sciences Co. (NASDAQ:EXAS) by 7.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,495 shares of the medical research company’s stock after selling 545 shares during the period. CHICAGO TRUST Co NA’s holdings in Exact Sciences were worth $274,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Park Avenue Securities LLC raised its stake in Exact Sciences by 14.5% in the second quarter. Park Avenue Securities LLC now owns 32,527 shares of the medical research company’s stock valued at $1,374,000 after buying an additional 4,127 shares in the last quarter. Thompson Investment Management Inc. raised its stake in Exact Sciences by 20.9% in the second quarter. Thompson Investment Management Inc. now owns 194,071 shares of the medical research company’s stock valued at $8,200,000 after buying an additional 33,487 shares in the last quarter. DNB Asset Management AS raised its stake in Exact Sciences by 47.1% in the second quarter. DNB Asset Management AS now owns 239,883 shares of the medical research company’s stock valued at $10,135,000 after buying an additional 76,847 shares in the last quarter. Moody National Bank Trust Division raised its stake in Exact Sciences by 8.4% in the second quarter. Moody National Bank Trust Division now owns 9,573 shares of the medical research company’s stock valued at $404,000 after buying an additional 741 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Exact Sciences by 48.4% during the second quarter. GAMMA Investing LLC now owns 1,362 shares of the medical research company’s stock worth $58,000 after purchasing an additional 444 shares during the last quarter. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Evercore ISI reduced their price target on shares of Exact Sciences from $80.00 to $72.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Canaccord Genuity Group decreased their price target on shares of Exact Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Thursday, May 9th. Jefferies Financial Group assumed coverage on Exact Sciences in a research note on Monday, June 3rd. They set a “buy” rating and a $75.00 target price for the company. Scotiabank assumed coverage on Exact Sciences in a research note on Thursday, June 27th. They set a “sector outperform” rating and a $70.00 target price for the company. Finally, BTIG Research lowered their target price on Exact Sciences from $80.00 to $70.00 and set a “buy” rating for the company in a research note on Wednesday, June 26th. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Exact Sciences currently has an average rating of “Moderate Buy” and an average target price of $78.77.

Exact Sciences Trading Down 0.4 %

NASDAQ EXAS traded down $0.25 on Friday, hitting $57.01. 1,718,028 shares of the stock were exchanged, compared to its average volume of 2,711,871. Exact Sciences Co. has a 52-week low of $40.62 and a 52-week high of $87.11. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.17 and a quick ratio of 1.45. The company has a market capitalization of $10.52 billion, a price-to-earnings ratio of -43.19 and a beta of 1.22. The company’s 50-day moving average price is $46.37 and its two-hundred day moving average price is $55.85.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Wednesday, July 31st. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.28. The business had revenue of $699.26 million during the quarter, compared to analyst estimates of $690.02 million. Exact Sciences had a negative net margin of 6.70% and a negative return on equity of 4.97%. Exact Sciences’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.45) EPS. Research analysts predict that Exact Sciences Co. will post -1.17 EPS for the current year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.